 | |
| Clinical data | |
|---|---|
| Pronunciation | /juːˈkrɪsə/ yoo-KRIS-ə |
| Trade names | Eucrisa, Staquis |
| Other names | AN-2728 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a617019 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Topical (ointment) |
| Drug class | PDE-4 inhibitor[1] |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C14H10BNO3 |
| Molar mass | 251.05 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Crisaborole, sold under the brand name Eucrisa among others, is a medication used to treat atopic dermatitis (eczema).[1][2] It is used for mild to moderate disease in those over the age of two months.[1] It is applied to the skin.[1]
Common side effects include burning or stinging at the site of application.[2] Other side effects may include allergic reactions.[1] It is a phosphodiesterase 4 (PDE-4) inhibitor and beleived to work by blocking the release of cytokines.[1][2]
Crisaborole was approved for medical use in the United States in 2016 and Europe in 2020.[1][2] In the United States a tube of 60 grams costs about 680 USD as of 2022.[3] While it is approved in the United Kingdom, it is not commercially available as of 2022.[4]
References
edit- ^ a b c d e f g h "Eucrisa- crisaborole ointment". DailyMed. 21 April 2020. Archived from the original on 23 March 2021. Retrieved 28 April 2020.
- ^ a b c d e f "Staquis EPAR". European Medicines Agency (EMA). 29 January 2020. Archived from the original on 2 November 2021. Retrieved 28 April 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "Crisaborole Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 7 January 2022.
- ^ "Crisaborole". SPS - Specialist Pharmacy Service. 8 January 2016. Archived from the original on 11 October 2021. Retrieved 7 January 2022.